BillionToOne, Inc.
BillionToOne, Inc. (Nasdaq: BLLN) develops and sells molecular diagnostic tests using a proprietary single-molecule next-generation sequencing platform to analyze cell-free DNA from blood samples. Its prenatal UNITY portfolio provides screening for recessive genetic conditions, chromosomal abnormalities and fetal… From the company’s description.
In fiscal 2025, BillionToOne, Inc. reported revenue of $305.11M and net income of $7.45M. Its operating margin was 5.3%, and operations generated $24.59M in cash. Over the twelve months to Sep 30, 2026, revenue was $436.87M.
Dotted labels explain each measure. is shown separately from the annual figures.
What BillionToOne, Inc. does
In the company’s own words
BillionToOne, Inc. (Nasdaq: BLLN) develops and sells molecular diagnostic tests using a proprietary single-molecule next-generation sequencing platform to analyze cell-free DNA from blood samples. Its prenatal UNITY portfolio provides screening for recessive genetic conditions, chromosomal abnormalities and fetal blood-cell antigens, using a maternal blood draw without requiring a paternal sample for fetal risk assessment. Its oncology portfolio serves patients with advanced solid tumors and their clinicians: Northstar Select profiles cancer-related genetic alterations to inform therapy selection, while Northstar Response measures cancer-associated DNA methylation to monitor tumor burden and treatment response. Additional Northstar applications address chemotherapy safety and clonal hematopoiesis. The company’s platform combines synthetic Quantitative Counting Templates with machine-learning and bioinformatics methods to quantify DNA targets. BillionToOne launched UNITY in 2019 and entered oncology in 2023; its tests are used by obstetric providers, oncologists and other healthcare customers. In 2025, more than 95% of oncologists who ordered its tests used both Northstar Select and Northstar Response.
Company details
- Sector
- Health Care
- Industry (SIC)
- Health Services
- Headquarters
- MENLO PARK, CA
- Fiscal year end
- December
- CIK
- 2070849
- SIC
- 8071
Financial performance, year by year
Fiscal 2025–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns BillionToOne, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in BillionToOne, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · BillionToOne, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do BillionToOne, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of BillionToOne, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in BillionToOne, Inc.'s last four quarterly filings that the numbers alone won't show?”